Expression Patterns of Immune Checkpoints in Breast Cancer Patients

Dan Qiu, Xianxin Yan, Guijuan Zhang, Xinqin Xiao, Jingyu Cao, Yanqiu Wang, Ruirui Ma, S.k. Hong, Min MaResearch 2021 · DOI

Introduction

Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has fundamentally changed the treatment landscape for various solid tumors, significantly improving overall survival (OS). While positive responses to PD-1/PD-L1 blockades have been observed across many malignancies, the efficacy of these therapies in breast cancer (BC) remains comparatively poor. A primary obstacle to improving these outcomes is the incomplete understanding of immune checkpoint expression patterns and their interactions within the breast cancer immune microenvironment. This study aims to map these patterns to identify robust prognostic biomarkers and potential targets for combinational therapy.

Methodology

This research utilized a multi-pronged approach, integrating large-scale bioinformatic analysis with in vitro validation:

  1. Bioinformatic Screening: The microarray dataset GSE10810 from the Gene Expression Omnibus (GEO) was analyzed to identify differentially expressed genes (DEGs) in breast cancer tissue compared to normal controls. Functional enrichment was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) via the DAVID database.
  2. Survival and Correlation Analysis: Data from 657 BC patients in The Cancer Genome Atlas (TCGA) were used to correlate gene expression and mutations with 20-year overall survival (OS). Additionally, expression levels were validated across 1,085 BC patients and 291 healthy controls using the Genotype-Tissue Expression (GTEx) database.
  3. Experimental Validation: mRNA levels of key checkpoints (PD-L1, STAT1, IDO, IFNγ-R) were measured using Real-time quantitative PCR (RQ-PCR) across a spectrum of cell lines: MCF-10A (non-tumorigenic), MCF-7 (luminal), and MDA-MB-231 (highly aggressive/triple-negative).

Results and Discussion

Pathway Enrichment and Survival Impact

Initial analysis of the GSE10810 dataset identified significant differential gene expression, with functional enrichment pointing toward critical roles in immune response and signaling pathways. Survival analysis revealed that high expression of individual checkpoints—specifically PD-1, PD-L1, STAT1, and CTLA-4—was significantly associated with poor OS. For instance, in the TCGA cohort, patients with high PD-1 expression exhibited a 20-year OS of 0%, compared to 35.09% in the low-expression group ($P=0.002$).

Differential gene expression, pathway enrichment, and survival analysis of immune checkpoints in breast cancer.

The Power of Co-expression

The study found that the prognostic value of these markers increases when analyzed in combination. Pairwise co-expression of PD-L1 with STAT1, PD-1, or CTLA-4, as well as PD-1 with CTLA-4, was strongly linked to poor clinical outcomes. Notably, the 20-year OS for patients with high co-expression of PD-L1 and STAT1 was 0%, whereas patients with low expression of both markers had an OS of 39.43%.

Subtype and Stage Specificity

Expression patterns varied significantly across clinical stages and molecular subtypes. The highest levels of immune-suppressive markers were found in Basal-like (Triple-Negative) breast cancer, which may explain the aggressive nature of this subtype. Interestingly, the expression of PD-L1 and IDO1 was found to decrease in Stage IV patients compared to earlier stages, suggesting a shift in the immune landscape as the disease progresses to a metastatic state.

In Vitro Validation

RQ-PCR results confirmed the bioinformatic findings. As cell lines progressed from non-tumorigenic to highly aggressive (MCF-10A → MCF-7 → MDA-MB-231), there was a significant increase in the expression of PD-L1 ($P=0.016$) and STAT1 ($P=0.025$). This supports the hypothesis that STAT1 may facilitate anti-tumor immune evasion by upregulating PD-L1.

Conclusion

The findings suggest that the transcriptome-based co-expression of STAT1 and PD-L1 is a potent predictor of poor overall survival in breast cancer patients. While STAT1 is traditionally viewed as a growth inhibitor, its role in upregulating PD-L1 highlights it as a potential target for combinational therapy. Future research should focus on the mechanistic pathways of this interaction and validate these findings at the protein level through immunohistochemistry to facilitate clinical translation.

Summary updated

Abstract

Abstract Background: immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival (OS). Positive response to PD-1/PD-L1 blockades was observed in the treatment of solidtumors. Breast cancer (BC) patients are no exception. However, the efficacy of immunocheckpoint therapy in BC patients remains poor. A particularly important factor is the lack of studies on the expression patterns of immune checkpoints in BC patients. Method: in this study, the microarray dataset GSE10810 was downloaded from the Gene Expression Database Synthesis (GEO) to analyze the differential expression of BC genes and perform GO and KEGG analysis. Then, we explored theprognostic value of ICs for BC patients by analyzing RNA-seq and mutation data from 657 BC patients from theCancer Genome Atlas (TCGA) database. Next, we analyzed the differences in the expression of relevant immune checkpoints between 1085 BC patients and 291 healthy controls (HC) in the Genotype-Tissue Expression (GTEx) database. Finally, we analyzed the expression levels of IFNγ-R, PD-L1, STAT1, IDO and other genes in MCF-10A, MF-10AT, MCF-7, MDA-MB-231 cell lines. Results: It was found that increased expression of PD-1, PD-L1, STAT1, CTLA-4 was associated with poor OS in BC patients. In addition, co-expression of PD-L1 with PD-1, STAT1or CTLA-4 and co-expression of PD-1 with CTLA-4was related to poor OS. We analyzed associations between the proportionate expression of PD-L1 and PD-1, PD-L1 and STAT1, PD-1 and CTLA-4, PD-1 and LAG3, PD-L1 and CTLA-4 in BC patients, there was significance in correlation in both of the BC patients.The expression of STAT1 in BC patients was compared with that of HC, and it was found that STAT1 was highly expressed in BC patients. Conclusions: our results suggest that transcriptome-based co-expression of STAT1 and PD-L1 is a predictor for poor OS in BC patients, which might provide novel insight into designing combinational targeted therapy for BC.
BibTeX
@inproceedings{qiu2021expression,
  author = {Dan Qiu and Xianxin Yan and Guijuan Zhang and Xinqin Xiao and Jingyu Cao and Yanqiu Wang and Ruirui Ma and S.K. Hong and Min Ma},
  title = {{Expression Patterns of Immune Checkpoints in Breast Cancer Patients}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-678853/v1},
}
Figure